Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 2Sarcoma 2Gastrointestinal 2Other hematologic neoplasm 1NET 1Head & Neck 1Gynecologic 1Genitourinary 1Endocrine 1CNS 1

Conditions

Gliosarcoma 1Glioblastoma 1

Interventions

Temozolomide 165Magnetic Resonance Spectroscopy 130Radiotherapy 95Specimen Handling 80Radiosurgery 60Cyclophosphamide 55pembrolizumab 51Bevacizumab 51Nivolumab 48Radiation 47Carboplatin 34Biopsy 33Irinotecan 29Lomustine 25Etoposide 25Vincristine 23Topotecan 23Ipilimumab 23dinutuximab 21Cisplatin 21Blood Specimen Collection 21fludarabine 19Radiotherapy, Intensity-Modulated 19X-Rays 18Surgical Procedures, Operative 18abemaciclib 16Mental Status and Dementia Tests 16Granulocyte-Macrophage Colony-Stimulating Factor 16Pemetrexed 15atezolizumab 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
peposertib × CNS × 1 year × Clear all
NCT04555577 2026-05-20

Peposertib and Radiation Therapy, Followed by Temozolomide for the Treatment of Patients With Newly Diagnosed MGMT Unmethylated Glioblastoma or Gliosarcoma

M.D. Anderson Cancer Center

Phase 1 Recruiting
29 enrolled
CNSSarcoma

Glioblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡